1
|
Han TT, Fan L, Li JY and Xu W: Role of
chemokines and their receptors in chronic lymphocytic leukemia:
function in microenvironment and targeted therapy. Cancer Biol
Ther. 15:3–9. 2014. View Article : Google Scholar :
|
2
|
Huang F and Geng XP: Chemokines and
hepatocellular carcinoma. World J Gastroenterol. 16:1832–1836.
2010. View Article : Google Scholar : PubMed/NCBI
|
3
|
Murphy PM: Chemokines and the molecular
basis of cancer metastasis. N Engl J Med. 345:833–835. 2001.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Steiner JL and Murphy EA: Importance of
chemokine (CC-motif) ligand 2 in breast cancer. Int J Biol Markers.
27:e179–e185. 2012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Singh V, Srivastava N, Srivastava P and
Mittal RD: Impact of CCL2 and Its Receptor CCR2 Gene Polymorphism
in North Indian Population: A Comparative Study in Different Ethnic
Groups Worldwide. Indian J Clin Biochem. 28:259–264. 2013.
View Article : Google Scholar :
|
6
|
Heare T, Hensley MA and Dell’Orfano S:
Bone tumors: osteosarcoma and Ewing’s sarcoma. Curr Opin Pediatr.
21:365–372. 2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Picci P: Osteosarcoma (osteogenic
sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Bielack SS, Kempf-Bielack B, Delling G, et
al: Prognostic factors in high-grade osteosarcoma of the
extremities or trunk: an analysis of 1,702 patients treated on
neoadjuvant cooperative osteosarcoma study group protocols. J Clin
Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
9
|
Lazennec G and Richmond A: Chemokines and
chemokine receptors: new insights into cancer-related inflammation.
Trends Mol Med. 16:133–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Lin ZY, Chuang YH and Chuang WL:
Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and
LOXL2 genes related to promotion of cancer progression in
hepatocellular carcinoma cells. Biomed Pharmacother. 66:525–529.
2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Fang WB, Jokar I, Zou A, Lambert D,
Dendukuri P and Cheng N: CCL2/CCR2 chemokine signaling coordinates
survival and motility of breast cancer cells through Smad3 protein-
and p42/44 mitogen-activated protein kinase (MAPK)-dependent
mechanisms. J Biol Chem. 287:36593–36608. 2012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kudo-Saito C, Shirako H, Ohike M,
Tsukamoto N and Kawakami Y: CCL2 is critical for immunosuppression
to promote cancer metastasis. Clin Exp Metastasis. 30:393–405.
2013. View Article : Google Scholar
|
13
|
Qian BZ, Li J, Zhang H, et al: CCL2
recruits inflammatory monocytes to facilitate breast-tumour
metastasis. Nature. 475:222–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Zhang J, Lu Y and Pienta KJ: Multiple
roles of chemokine (C-C motif) ligand 2 in promoting prostate
cancer growth. J Natl Cancer Inst. 102:522–528. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Sarvaiya PJ, Guo D, Ulasov I, Gabikian P
and Lesniak MS: Chemokines in tumor progression and metastasis.
Oncotarget. 4:2171–2185. 2013.PubMed/NCBI
|
16
|
Chiu HY, Sun KH, Chen SY, et al: Autocrine
CCL2 promotes cell migration and invasion via PKC activation and
tyrosine phosphorylation of paxillin in bladder cancer cells.
Cytokine. 59:423–432. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Zhang J, Patel L and Pienta KJ: CC
chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis
and metastasis. Cytokine Growth Factor Rev. 21:41–48. 2010.
View Article : Google Scholar :
|
18
|
Roca H, Varsos Z and Pienta KJ: CCL2
protects prostate cancer PC3 cells from autophagic death via
phosphatidylinositol 3-kinase/AKT-dependent survivin upregulation.
J Biol Chem. 283:25057–25073. 2008. View Article : Google Scholar : PubMed/NCBI
|
19
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
20
|
Behnke NK, Alamanda VK, Song Y, et al:
Does postoperative infection after soft tissue sarcoma resection
affect oncologic outcomes? J Surg Oncol. 109:415–420. 2014.
View Article : Google Scholar
|
21
|
1von Luettichau I, Segerer S,
Wechselberger A, et al: A complex pattern of chemokine receptor
expression is seen in osteosarcoma. BMC Cancer. 8:232008.
View Article : Google Scholar
|
22
|
Lu Y, Cai Z, Galson DL, et al: Monocyte
chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine
factor for prostate cancer growth and invasion. Prostate.
66:1311–1318. 2006. View Article : Google Scholar : PubMed/NCBI
|
23
|
Rhodes DR, Yu J, Shanker K, et al:
ONCOMINE: a cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
24
|
Sukawa Y, Yamamoto H, Nosho K, et al: HER2
expression and PI3K-Akt pathway alterations in gastric cancer.
Digestion. 89:12–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Wang Q, Ding H, Liu B, et al: Addition of
the Akt inhibitor triciribine overcomes antibody resistance in
cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors. Int J
Oncol. 44:1277–1283. 2014.PubMed/NCBI
|
26
|
Kuijjer ML, van den Akker BE, Hilhorst R,
et al: Kinome and mRNA expression profiling of high-grade
osteosarcoma cell lines implies Akt signaling as possible target
for therapy. BMC Med Genomics. 7:42014. View Article : Google Scholar : PubMed/NCBI
|
27
|
Pienta KJ, Machiels JP, Schrijvers D, et
al: Phase 2 study of carlumab (CNTO 888), a human monoclonal
antibody against CC-chemokine ligand 2 (CCL2), in metastatic
castration-resistant prostate cancer. Invest New Drugs. 31:760–768.
2013. View Article : Google Scholar
|